CDK12 loss-of-function mutations are detected in malignancies with highly unstable genome, such as high-graded serous ovarian carcinomas and metastatic-castration resistant prostate cancers [37,38,39]. This evidence concerns the gene CDK12 and ovarian serous carcinoma.